# Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

> clinical trial · VERIFIED · 2026-07-10

Status: RECRUITING · Sponsor: Tianjin Medical University Cancer Institute and Hospital · Condition: Pancreatic Cancer, Adult

- Company: Tianjin Medical University Cancer Institute and Hospital
- Sector: Pancreatic Cancer, Adult
- Primary source: https://clinicaltrials.gov/study/NCT07436741

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.